Immunomodulatory effects of interferon-β-1b in patients with multiple sclerosis

The mechanisms by which IFNβ-1b acts in the treatment of patients with multiple sclerosis (MS) are not completely known. Immunomodulatory effects of IFNβ-1b were investigated in patients with relapsing–remitting (RR) MS in vivo and in vitro. Compared to baseline and controls, defined as patients wit...

Full description

Saved in:
Bibliographic Details
Published in:International Immunopharmacology 2001-06, Vol.1 (6), p.1085-1100
Main Authors: Ossege, L.M, Sindern, E, Patzold, T, Malin, J.-P
Format: Article
Language:English
Subjects:
Immunomodulatory therapy
Interferon-beta-1b
Lymphocyte subsets
Multiple sclerosis
Soluble vascular adhesion molecule-1
TGFβ beta receptor type II
TGFβ-1
TNFα
TNFα receptor type I
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mechanisms by which IFNβ-1b acts in the treatment of patients with multiple sclerosis (MS) are not completely known. Immunomodulatory effects of IFNβ-1b were investigated in patients with relapsing–remitting (RR) MS in vivo and in vitro. Compared to baseline and controls, defined as patients with RR-MS without immunomodulatory therapy, the expression of TGFβ-1-mRNA by peripheral blood mononuclear cells (PBMC) was persistently increased at week 6, month 3 and month 6 ( p≤0.05), that of the TGFβ-1 receptor type II from day 5 up to month 6 ( p
ISSN:1567-5769
1878-1705
DOI:10.1016/S1567-5769(01)00039-X